neoantigen-targeted dendritic cell T-cell therapy

Neoantigen-targeted dendritic cell T-cell therapy is a personalized cellular immunotherapy developed by the Department of Biotherapy and Cancer Center at West China Hospital, Sichuan University. This therapeutic approach involves a dual-component strategy: a dendritic cell (DC) vaccine and adoptive T-cell therapy. First, patient-specific tumor mutations (neoantigens) are identified through next-generation sequencing (NGS) and bioinformatic analysis of tumor biopsies. Autologous dendritic cells are then loaded (pulsed) with these neoantigens to create a vaccine designed to prime and activate the patient's immune system. Simultaneously, neoantigen-reactive T cells (NRTs) are identified, isolated, and expanded ex vivo. The combined administration of the DC vaccine and the expanded T cells aims to overcome the immunosuppressive tumor microenvironment and induce a potent, highly specific cytotoxic response against tumor cells expressing those unique mutations. This therapy is primarily being investigated for advanced solid tumors, including melanoma, bladder cancer, and colorectal cancer.

Other names

Neoantigen-pulsed Dendritic Cells and Neoantigen-specific T CellsNeo-DC vaccine plus Neo-T cell therapyPersonalized Neoantigen-targeted Immunotherapy